

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Brian J. Windsor et al.

Serial No.: 10/531,744

Filed: April 18, 2005

For: METHODS AND COMPOSITIONS FOR
INCREASING THE EFFICACY OF
BIOLOGICALLY-ACTIVE
INGREDIENTS

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: TEXG:010US

CERTIFICATE OF ELECTRONIC SUBMISSION

DATE OF SUBMISSION: August 3, 2006

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/TEXG:010US.

Each item of information contained in this Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application, as evidenced by the enclosed search report.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Robert E. Hanson
Reg. No. 42,628
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: August 3, 2006

Form PTO-1449 (modified)		Atty. Docket No. TEXG:010US	Serial No. 10/531,744
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Brian J. Windsor <i>et al.</i>	
		Filing Date: April 18, 2005	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A6	2002/0077365	6/20/02	Windsor <i>et al.</i>	514	621	9/7/01
	A7	2002/0103082	8/1/02	Windsor <i>et al.</i>	504	116.1	3/6/01
	A8	4,737,521	4/12/98	Stunkel <i>et al.</i>	514	577	5/27/86

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C63	Yunbam et al. "In vivo evaluation of reuterin and its combinations with suramin, melarsoprol, DL-alpha-defluoromethylornithine and bleomycin in mice infected with Trypanosoma brucei brucei" <i>Comp Biochem Physiol</i> , 105C(3):521-524, 1993.

25672508.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.